Prudential Financial
CLDX icon

Prudential Financial’s Celldex Therapeutics CLDX Stock Holding History

Prudential Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Buy
16,698
+6,295
+61% +$203K ﹤0.01% 1829
2026
Q1 		$330K Buy
+10,403
New +$284K ﹤0.01% 1997
2025
Q4 		– Sell
-8,809
Closed -$228K – 2256
2025
Q3 		$228K Buy
+8,809
New +$204K ﹤0.01% 2186
2024
Q4 		– Sell
-68,471
Closed -$2.33M – 2347
2024
Q3 		$2.33M Sell
68,471
-4,430
-6% -$169K ﹤0.01% 1414
2024
Q2 		$2.7M Buy
72,901
+58,815
+418% +$2.22M ﹤0.01% 1245
2024
Q1 		$591K Buy
+14,086
New +$578K ﹤0.01% 2106
2023
Q3 		– Sell
-57,601
Closed -$1.95M – 2611
2023
Q2 		$1.95M Sell
57,601
-37,000
-39% -$1.25M ﹤0.01% 1424
2023
Q1 		$3.4M Sell
94,601
-20,015
-17% -$864K 0.01% 1029
2022
Q4 		$5.11M Buy
114,616
+32,995
+40% +$1.18M 0.01% 857
2022
Q3 		$2.29M Buy
+81,621
New +$2.5M ﹤0.01% 1259
2021
Q4 		– Sell
-3,883
Closed -$210K – 2645
2021
Q3 		$210K Buy
+3,883
New +$182K ﹤0.01% 2460
2018
Q2 		– Sell
-704
Closed -$25K – 2434
2018
Q1 		$25K Hold
704
– – ﹤0.01% 2335
2017
Q4 		$30K Buy
704
+7
+1% +$300 ﹤0.01% 2319
2017
Q3 		$30K Sell
697
-39
-5% -$1.46K ﹤0.01% 2321
2017
Q2 		$27K Buy
+736
New +$32.6K ﹤0.01% 2329
2016
Q1 		– Sell
-7,999
Closed -$1.88M – 2302
2015
Q4 		$1.88M Sell
7,999
-7
-0.1% -$1.53K ﹤0.01% 1535
2015
Q3 		$1.27M Buy
8,006
+7
+0.1% +$1.98K ﹤0.01% 1675
2015
Q2 		$3.03M Hold
7,999
– – 0.01% 1356
2015
Q1 		$3.34M Buy
7,999
+33
+0.4% +$11.8K 0.01% 1336
2014
Q4 		$2.18M Sell
7,966
-153
-2% -$38K ﹤0.01% 1428
2014
Q3 		$1.58M Sell
8,119
-700
-8% -$153K ﹤0.01% 1543
2014
Q2 		$2.16M Buy
8,819
+693
+9% +$156K ﹤0.01% 1471
2014
Q1 		$2.15M Sell
8,126
-6
-0.1% -$2.3K ﹤0.01% 1430
2013
Q4 		$2.95M Sell
8,132
-14
-0.2% -$5.39K 0.01% 1242
2013
Q3 		$4.33M Sell
8,146
-4,166
-34% -$1.43M 0.01% 1012
2013
Q2 		$2.88M Buy
+12,312
New +$2.42M 0.01% 1171

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prudential Financial's CLDX Position: Q2 2026 in Review

Prudential Financial increased its Celldex Therapeutics (CLDX) stake by 61% in Q2 2026, buying an estimated $203K and bringing the position to 16,698 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Prudential Financial first reported a position in CLDX in Q2 2013 and has held it in 26 quarters since. The position peaked at $5.11M in Q4 2022. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Prudential Financial held 16,698 shares of Celldex Therapeutics worth $621K as of Q2 2026.
  • Prudential Financial bought 6,295 Celldex Therapeutics shares in Q2 2026, an estimated $203K.
  • Celldex Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1829 holding.
  • Prudential Financial first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 26 quarters since.
  • Prudential Financial's Celldex Therapeutics position peaked at $5.11M in Q4 2022.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.